HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • The HEOR & RWE Marketplace
    • Visit the Market Place
    • On-demand Webinar
  • Industry Events
    • 5 Tips for Trade Show Success
    • HE Innovation Webinar
    • Webinar Services from HealthEconomics.Com
    • View Conferences
    • View Webinars
    • View Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute
You are here: Home / Featured / Former FDA Commish Califf: Weighing the Benefits & Risks of the Growing Number of Observational Treatment Assessments

Former FDA Commish Califf: Weighing the Benefits & Risks of the Growing Number of Observational Treatment Assessments

In a recently published JAMA Viewpoint, former FDA Commissioner Robert Califf and colleagues mused about a growing concern about inferring causation about benefits and risks of potential therapeutics for COVID-19 derived from nonrandomized studies.  The authors mused, ” whether these reports just add noise, confusion, and false confidence.” Does this approach help contribute to the knowledge and the need for well-designed randomized clinical trials and accelerate their delivery?1 Or do observational studies reduce the likelihood of a properly designed trial being performed, thereby delaying the discovery of reliable truth?

The authors warn healthcare providers, patients, and policymakers to stop the rush to judgment in the absence of reliable evidence, the proliferation of observational treatment comparisons will hinder the goal of finding effective treatments for COVID-19—and a great many other diseases.

(Source:  Califf RM, et al., JAMA, July 31, 2020)



You might also be interested in:

  • How HEOR Professionals Can Be Force Multipliers in the Fight… 10/06/2020
  • New Program in Pharmaceutical Value Assessment and… 01/22/2021
  • New Roadmap Aims to Transform Healthcare Landscape by… 08/13/2020
  • Trump's "Buy American" Executive Order Could Raise Drug Prices 08/06/2020
  • Robert Dubois, MD, PhD, Steps in as Interim President and CEO… 09/01/2020
  • What Does $11M in Donations to Congress Buy Pharma? 08/12/2020
  • Key Innovations Coming From The Next Generation of PBM’s 08/12/2020

 

View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Conference of the Week:

Link of the Week:

Job of the Week:

Webinar of the Week:

White Papers

  • Whitepaper: The Role of Centralized Care Management in Value-based Care
  • 2017 In-Depth Outlook on Oncology Report
  • Value-Based Healthcare: Making it Happen
  • Value-Based Contracting for Biopharmaceuticals Moves Forward
  • ICER Releases White Paper on Gene Therapy

Syndicated Reports

  • HTA in Europe: Key Success Factors for Positive HTA Recommendations
  • Paying for Digital Health: Payer Insights
  • Benchmarking Pharma’s MSL Capabilities
  • Biosimilars: US Payer Perspectives
  • KAM Metrics: Driving Efficiency, Measuring Success
HealthEconomics.Com

HealthEconomics.Com

  • News
  • Conferences
  • Reports
  • Jobs
  • Consulting
  • Newsletters
  • White Papers

More Links

  • Jobs
  • Education
  • Graduate Schools
  • Webinar Services

Support & Contact

  • Contact Us

About

  • About Us
  • Advertise
  • Webinar Services
  • HE Institute
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HE Institute

Strategy, Training, Education, and Communications in HEOR & Market Access.

Innovation Webinar

Big ideas accelerating change in HEOR, RWE and Health Technology. Learn more!

tHEORetically Speaking Blog

Insights and observations for HEOR, market access, pricing, reimbursement, and health policy.

HE Jobs Portal

Your Premier Employment Source for HEOR, Market Access, and Real World Evidence

HE Webinars

Online educational and informational seminars for HEOR, market access, pricing, and reimbursement.
  • HealthEconomics.Com
  • About HealthEconomics.Com
  • Advertising Inquiries
  • Careers
  • Contact HealthEconomics.Com

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • The HEOR & RWE Marketplace
    • Visit the Market Place
    • On-demand Webinar
  • Industry Events
    • 5 Tips for Trade Show Success
    • HE Innovation Webinar
    • Webinar Services from HealthEconomics.Com
    • View Conferences
    • View Webinars
    • View Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute